Emergent awarded $19.7m to make ZMapp-like Ebola cocktail

Emergent BioSolutions snagged a $19.7m contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture three Ebola monoclonal antibodies (mAbs), which are the same as those used to make Mapp Biopharmaceuticals' ZMapp – a drug that gained quick fame last year at the height of the Ebola outbreak in West Africa.